Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next Generation Blood Separation Technology Receives CE Marking

By LabMedica International staff writers
Posted on 27 Mar 2016
A next-generation blood separation technology that is designed to enhance sample quality, improve laboratory efficiency and reduce laboratory turnaround time has received the Conformité Européenne (CE) marking. More...


The tube is a single-use, plastic evacuated tube used to collect, separate, transport and process venous blood specimens to obtain high-quality plasma for in vitro diagnostic use and the tube has a revolutionary separator technology, providing a cleaner plasma sample with less cellular contamination, meaning the sample is more stable and allows a longer window to conduct testing when compared to existing blood separation tubes.

BD Barricor tubes (BD, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) are optimized to deliver a high quality plasma sample by reducing cellular content (versus plasma gel tubes), as a result of the mechanical separator remaining open throughout the centrifugation cycle. It eliminates gel artifacts which can lead to instrument downtime. These factors together with longer sample stability can significantly improve the sample and laboratory workflow.

The tube has a revolutionary separator technology, providing a cleaner plasma sample with less cellular contamination, meaning the sample is more stable and allows a longer window to conduct testing when compared to existing blood separation tubes. The Barricor tubes deliver a faster time-to-result for patients, with no clotting time required and a reduction in centrifugation time of up to seven minutes, an overall saving in turnaround time of 37 minutes is possible.

Lisa Nibauer, MBA, vice president and general manager of Global Marketing for BD Life Sciences, said, “Laboratory technicians are forced to choose between a clean sample with serum and a fast sample with plasma. BD Barricor tubes eliminate this tradeoff, providing a cleaner and faster plasma sample than current methods.”

Related Links:

Becton, Dickinson and Company 



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Test
Allplex HPV28 Detection
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.